Predictive Value of the Uric Acid/Albumin Ratio and Lactate in Sepsis Patients (NCT07332715) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Predictive Value of the Uric Acid/Albumin Ratio and Lactate in Sepsis Patients
Turkey (Türkiye)80 participantsStarted 2026-01-15
Plain-language summary
Sepsis is a life-threatening condition characterized by organ dysfunction resulting from a dysregulated host response to infection and remains a leading cause of morbidity and mortality in intensive care units. Early identification of patients at high risk for adverse outcomes is essential for timely intervention and improved prognosis.
This prospective, single-center, non-interventional study aims to evaluate the predictive value of the combined use of the blood uric acid/albumin ratio (UAR) and serum lactate levels in patients aged 65 years and older who are admitted to the intensive care unit with a diagnosis of sepsis according to SEPSIS-3 criteria. Patients without acute kidney injury at admission and with at least 24 hours of intensive care follow-up will be included.
The primary outcome is the development of acute kidney injury within the first 7 days of ICU admission according to KDIGO criteria. Secondary outcomes include vasopressor requirement during ICU stay, changes in serum lactate levels over the first 24 hours, and 28-day mortality. The study seeks to determine whether the combination of UAR and lactate levels can serve as an easily accessible and clinically applicable biomarker to predict adverse outcomes and support prognostic assessment and treatment strategies in sepsis patients.
Who can participate
Age range
65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients aged 65 years and older
* Diagnosis of sepsis according to SEPSIS-3 criteria
* Admission to the intensive care unit
* No acute kidney injury at admission according to KDIGO classification
* Measurement of serum uric acid, albumin, and lactate levels at ICU admission
* SOFA score calculated at ICU admission
* ICU follow-up of at least 24 hours
Exclusion Criteria:
* Age under 65 years
* Uncompensated or decompensated chronic liver disease (e.g., Child-Pugh class C)
* Chronic kidney disease stage 4 or 5 (eGFR \<30 mL/min/1.73 m²)
* Presence of acute kidney injury at admission according to KDIGO criteria
* Active malignancy or receipt of active cancer treatment within the last 6 months
* Missing or incomplete clinical/laboratory data
* ICU follow-up less than 24 hours
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Development of Acute Kidney Injury (AKI)
Timeframe: Within the first 7 days following intensive care unit admission